Factors Affecting the Price of Camzyos

Factors Affecting the Price of Camzyos

1. Specialty Drug Status & REMS Program: Its restricted distribution (CAMZYOS REMS Program) due to serious risks like heart failure necessitates complex management, increasing operational costs.

2. Complex Dosing & Monitoring: Requiring individualized dosing based on frequent echocardiograms (LVEF, LVOT gradient) adds significant healthcare resource utilization and monitoring costs.

3. Significant R&D Investment: The extensive clinical trials (EXPLORER-HCM, VALOR-HCM) detailed demonstrate substantial development costs for this first-in-class cardiac myosin inhibitor.

4. Target Population: It treats a relatively small, specific population (symptomatic obstructive HCM adults, NYHA II-III), limiting economies of scale.

6. Patent Protection: As a recently approved drug (2022), Camzyos benefits from market exclusivity, allowing the manufacturer to set prices without generic competition.